Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

Inclusion Criteria:

• • Male Chinese participants <= 65 years of age.

• • Participants with severe hemophilia A (FVIII activity < 1%).

• • Participants who have received FVIII products for >= 150 EDs (>= 6 years of age)or >= 50 EDs (< 6 years of age).

Exclusion Criteria:

• • Known hypersensitivity (allergic reaction or anaphylaxis) to any FVIII product orhamster protein.

• • Known congenital or acquired coagulation disorder other than congenital FVIIIdeficiency.

• • Currently receiving intravenous (IV) immunomodulating agents such asimmunoglobulin or chronic systemic corticosteroid treatment.

• • Receiving any cryoprecipitate, whole blood, or plasma within 30 days beforeadministration of rVIII-SingleChain.

• • Use of traditional or herbal Chinese medicine(s) with an impact on hemophilia,including coagulation, within 28 days before Day 1 and / or refusal to abstain fromthese during the study until the end of the participant's participation in thestudy.